赛诺菲交易后，Regeneron遭遇每股收益近0.18美元的阻力

2026-10-06 21:25

Days after announcing an expanded collaboration with its French partner Sanofi (SNY), Regeneron (REGN) on Tuesday disclosed that its net income per diluted share will be impacted by roughly $0.18 in Q3 2026 due to an R&D-related pre-tax charge of about $22M.
The acquired in-process research and development charge reflects asset acquisitions as well as upfront, milestone, and other payments paid on equity in connection with collaboration and licensing agreements.
On Thursday, Regeneron (REGN) and Sanofi (SNY) agreed to expand their long-standing collaboration in a deal worth up to $8B, including $1B paid to the U.S. drugmaker to develop and commercialize four long-acting immunology therapies.
The sixth amendment to the 2009 deal also requires the companies to share global profits on newly licensed products equally and Regeneron (REGN) to drop a lawsuit against the Paris-based pharma giant.

More on Regeneron Pharmaceuticals, Sanofi, etc.